ARTICLE | Clinical News
Apremilast: Phase III started
November 8, 2010 8:00 AM UTC
Celgene disclosed in its 3Q10 earnings that it began the double-blind, placebo-controlled Phase III PALACE 3 trial to evaluate twice-daily 20 or 30 mg apremilast in 495 patients. ...